loader
report-image

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size & Share - By Types (Single-photon Emission Computerized Tomography and Positron Emission Tomography) and Products (Fluorine-18, Carbon-11, and GA 68 PSMA) and By Region: Global & Forecast, 2024-2033

  • PUBLISHED ON
  • 2023-12-11
  • NO OF PAGES
  • 214
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Size is projected to achieve a value of USD 258.1 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 612.32 Million by 2033 with a CAGR of 10.2% during the forecast period 2024-2033.

 

SOURCE: We Market Research

Nuclear medicine diagnostics for prostate cancer entail imaging methods that assess and identify prostate cancer using radioactive materials. Prostate-specific membrane antigen (PSMA) ligands and radiotracers such as ~18F-fluorodeoxyglucose (FDG) are commonly used in PET scans. These tracers help with tumor identification, staging, and treatment response monitoring by drawing attention to malignant cells. These cutting-edge imaging technologies, which target particular molecules, offer comprehensive insights into the nature and spread of prostate cancer and help to shape successful treatment plans.

The growth of the U.S. prostate cancer nuclear medicine diagnostics market is propelled by several factors. The accuracy of detection is improved by technological developments in imaging methods, especially the creation of more sensitive and exact radiotracers like PSMA ligands. Aging populations and rising prostate cancer rates fuel market growth even further. Demand is also fueled by a greater understanding of the advantages of early detection and accurate staging by nuclear medicine imaging. The continuous attempts to enhance imaging modalities and treatment monitoring through research and development also play a major role in the market's growth.

Market Scope

Report Attributes

Description

Market Size in 2023

USD 258.1 Million

Market Forecast in 2033

USD 612.32 Million

CAGR % 2024-2033

10.2%

Base Year

2023

Historic Data

2016-2022

Forecast Period

2024-2033

Report USP

 

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

by Types, by Products and By Region

Regional Scope

North America

Country Scope

U.S

U.S. Prostate Cancer Nuclear Medicine Diagnostics Industry: Dynamics & Restrains

Market Drivers

Advancements in Nuclear Medicine Imaging - The U.S. Prostate Cancer Nuclear Medicine Diagnostics Market is driven by advancements in nuclear medicine imaging, particularly through PET and SPECT technologies, which have revolutionized precision and accuracy in cancer detection. Even at microscopic levels, improved radiopharmaceuticals and imaging methods provide unmatched sensitivity, allowing for the earlier and more accurate diagnosis of prostate cancer lesions. These developments provide doctors with thorough, specific information that is essential for precise prostate cancer staging, therapy planning, and progression tracking. As a result, these developments increase the need for nuclear medicine diagnostics, leading to better patient outcomes and individualized treatment plans.

Rising Emphasis on Early Detection and Personalized Medicine - The U.S. Prostate Cancer Nuclear Medicine Diagnostics Market is being driven primarily by the growing emphasis on early detection and individualized medicine. The significance of prompt intervention and customized treatment plans is emphasized by this emphasis. Due to the great sensitivity and specificity of nuclear medicine diagnostics, prostate cancer can be identified early and customized therapy can be started right away. These instruments offer in-depth understandings of the biology of diseases, which helps with the selection of focused therapies, tracking of treatment results, and reduction of side effects. Thus, the use of nuclear medicine in early detection is consistent with the move in healthcare toward precision medicine, which is driving the market by increasing treatment efficacy and patient outcomes.

Market Restrains

High Cost of Nuclear Medicine Procedures - The U.S. Prostate Cancer Nuclear Medicine Diagnostics Market is severely restricted by the high cost of nuclear medicine procedures. The costs associated with PET scans, radiopharmaceuticals, and specialist equipment are prohibitive for patients and healthcare providers alike. These high prices may prevent these sophisticated diagnostic instruments from being widely adopted and used by restricting their affordability and accessibility. Furthermore, strict reimbursement guidelines frequently fall short of fully covering these costs, which makes it further harder for patients to have nuclear medicine diagnostics for prostate cancer. In order to improve market penetration and provide fair access to these state-of-the-art diagnostic tools, it is imperative that these cost obstacles be addressed.

U.S. Prostate Cancer Nuclear Medicine Diagnostics Segmentation

Market- By Type Analysis

By Type, the U.S. Prostate Cancer Nuclear Medicine Diagnostics Market is Categories into Single-photon Emission Computerized Tomography and Positron Emission Tomography. The Positron Emission Tomography segment accounts for the largest share of around 68% in 2022.


As positron emission tomography generates better images and costs more than standard SPECT nuclear medicine diagnostic treatments, it is expected to hold a dominated market share during the forecast period.

The following segments are part of an in-depth analysis of U.S. Prostate Cancer Nuclear Medicine Diagnostics Market:

Market Segments

 

By  Products

·         Fluorine-18

·         Carbon-11

·         GA 68 PSMA

Pointers Covered

The U.S. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Report provides a comprehensive analysis of the market. The report discusses market segmentation, DROS, and the product portfolios of the key market player companies in the US industry. It also provides the launch or research of new drugs, moreover advancements in the sector including collaborations, mergers, and acquisitions, as well as the impact of the COVID-19 pandemic on the market. The study also offers insights into market trends and an analysis of industry dynamics.

Competitive Analysis

The U.S. Prostate Cancer Nuclear Medicine Diagnostics Market is dominated by a few large companies, such as

·         NCM-USA LLC

·         Blue Earth Diagnostics

·         Cardinal Health

·         CURIUM PHARMA

·         Lantheus

·         Jubilant Draximage Radiopharmacies, Inc.

·         Telix Pharmaceuticals Limited

·         Novartis AG

·         Life Molecular Imaging

·         ARICEUM THERAPEUTICS

·         Siemens Healthcare Private Limited 

·         Other

There are some of the key trends that are shaping the competitive landscape of the U.S. Prostate Cancer Nuclear Medicine Diagnostics Market.

·         October 2023, Novartis presented data at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrating that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) significantly improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after androgen receptor (AR) pathway inhibition and taxane chemotherapy.

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.

Frequently Asked Questions

What is the market size of U.S. Prostate Cancer Nuclear Medicine Diagnostics Market in 2022?

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market was valued at USD 187.31 Million in 2022.

What is the growth rate for the U.S. Prostate Cancer Nuclear Medicine Diagnostics Market?

U.S. Prostate Cancer Nuclear Medicine Diagnostics Market size will increase at approximate CAGR of 10.2% during the forecasted period.

Which are the top companies operating within the U.S. Prostate Cancer Nuclear Medicine Diagnostics Market?

CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI